Get the Stockscreener App
18.14
6.83%
1.16
After Hours:
18.17
0.03
+0.17%
Maplight Therapeutics Inc stock is traded at $18.14, with a volume of 173.40K.
It is up +6.83% in the last 24 hours and up +2.89% over the past month.
MapLight Therapeutics Inc is a biopharmaceutical company. The company is focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. The company is engaged in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. The product candidates of the company include ML-007C-MA, ML-004, ML-021, ML-009, and other pipeline products.
See More
Previous Close:
$16.98
Open:
$17.2
24h Volume:
173.40K
Relative Volume:
0.74
Market Cap:
$823.07M
Revenue:
-
Net Income/Loss:
$-100.00M
P/E Ratio:
-7.7123
EPS:
-2.3521
Net Cash Flow:
$-109.23M
1W Performance:
+6.58%
1M Performance:
+2.89%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$17.12
$18.32
1-Week Range:
$16.30
$18.36
52-Week Range:
$12.24
$21.55
Maplight Therapeutics Inc Stock (MPLT) Company Profile
Name
Maplight Therapeutics Inc
Sector
Industry
Phone
-
Address
-
Compare MPLT vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MPLT
Maplight Therapeutics Inc
|
18.14 | 770.43M | 0 | -100.00M | -109.23M | -2.3521 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Maplight Therapeutics Inc Stock (MPLT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-19-26 | Initiated | Canaccord Genuity | Buy |
| Nov-21-25 | Initiated | Jefferies | Buy |
| Nov-21-25 | Initiated | Leerink Partners | Outperform |
| Nov-21-25 | Initiated | Morgan Stanley | Overweight |
| Nov-21-25 | Initiated | Stifel | Buy |
Maplight Therapeutics Inc Stock (MPLT) Latest News
MapLight Therapeutics, Inc.(NasdaqGS: MPLT) added to S&P Global BMI Index - marketscreener.com
Maplight Therapeutics (NASDAQ:MPLT) Cut to Sell at Wall Street Zen - MarketBeat
MapLight Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | MPLT | US56565P1030 - marketscreener.com
Top Maplight Therapeutics (MPLT) Competitors 2026 - MarketBeat
Canaccord Genuity Group Begins Coverage on Maplight Therapeutics (NASDAQ:MPLT) - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Shares Down 3.1%Should You Sell? - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Stock Price Up 8.9%Here's What Happened - MarketBeat
MapLight Therapeutics to join Russell 3000, Russell 2000 and Russell Microcap indexes - MSN
MapLight Therapeutics: Sector Dynamics Take Center Stage Amid Company Quiet () - aktiencheck.de
Schizophrenia Clinical Trial Pipeline Expands as 55+ Pharma Companies Progress Novel Therapies Toward Market Entry, Finds DelveInsight | Sunovion Pharmaceuticals, AbbVie, Karuna Therapeutics - Barchart.com
Autistic Disorder Pipeline Expands with 25+ Companies and 25+ Therapies in Development Across Clinical Stages, Reveals DelveInsight - Barchart.com
Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives $31.00 Consensus Price Target from Analysts - Defense World
MapLight2026 Funding Rounds & List of Investors - Tracxn
MapLight $251M IPO Defies Market Slowdown Amid Federal Shutdown - USA Herald
MapLight Therapeutics to Participate in Upcoming Investor Conferences - Bitget
Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
MapLight Therapeutics Inc expected to post a loss of 99 cents a shareEarnings Preview - TradingView
MapLight Therapeutics Insider Makes a Major Move With Fresh Stock Sale - TipRanks
Maplight Therapeutics (NASDAQ:MPLT) Director Sells $13,358.40 in Stock - MarketBeat
Insider Selling: Maplight Therapeutics (NASDAQ:MPLT) Director Sells $39,575.85 in Stock - MarketBeat
Insider Selling: Maplight Therapeutics (NASDAQ:MPLT) Director Sells 11,264 Shares of Stock - MarketBeat
Director Malenka sells 14,195 MapLight (MPLT) shares to cover RSU taxes - Stock Titan
MapLight Therapeutics, Inc. Rings the Closing Bell - Nasdaq
Maplight Therapeutics (NASDAQ:MPLT) Shares Gap Up After Insider Buying Activity - Defense World
Insider Buying: George Pavlov Acquires 25,000 Shares of MapLight Therapeutics Inc (MPLT) - GuruFocus
Maplight Therapeutics (NASDAQ:MPLT) Director Acquires $177,171.20 in Stock - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Director Acquires $77,694.54 in Stock - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Director George Pavlov Purchases 10,658 Shares - MarketBeat
MapLight Therapeutics director Pavlov buys shares worth $441k By Investing.com - Investing.com Canada
MapLight Therapeutics Director Makes Bold Insider Move in Latest Stock Buy - TipRanks
Malenka Robert C. sells Maplight Therapeutics (MPLT) shares for $220,632 By Investing.com - Investing.com South Africa
Malenka Robert C. sells Maplight Therapeutics (MPLT) shares for $220,632 - Investing.com
Insider Selling: Maplight Therapeutics (NASDAQ:MPLT) Director Sells 12,116 Shares of Stock - MarketBeat
Forbion discloses 7.1% MapLight Therapeutics (MPLT) ownership stake - Stock Titan
Big Insider Shake-Up at MapLight Therapeutics as Directors Make Opposite Moves - TipRanks
Insider Selling: Maplight Therapeutics (NASDAQ:MPLT) Director Sells 6,622 Shares of Stock - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Director Timothy John Garnett Buys 14,124 Shares - MarketBeat
Capital Markets Group Of The Year: Cooley - Law360
Maplight Therapeutics (NASDAQ:MPLT) Shares Gap Down – Time to Sell? - Defense World
Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives $31.00 Average Price Target from Brokerages - Defense World
Maplight Therapeutics (NASDAQ:MPLT) Shares Gap DownTime to Sell? - MarketBeat
Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Malenka sells MapLight (MPLT) shares worth $126,860 By Investing.com - Investing.com Canada
Malenka sells MapLight (MPLT) shares worth $126,860 - Investing.com
Insider Selling: Maplight Therapeutics (NASDAQ:MPLT) Director Sells 7,039 Shares of Stock - MarketBeat
Insider Selling: Maplight Therapeutics (NASDAQ:MPLT) Director Sells $119,743.32 in Stock - Defense World
Malenka sells MapLight Therapeutics (MPLT) stock worth $635,857 By Investing.com - Investing.com India
Maplight Therapeutics (NASDAQ:MPLT) Director Robert Malenka Sells 6,524 Shares of Stock - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Director Robert Malenka Sells 21,262 Shares - MarketBeat
Maplight Therapeutics Inc Stock (MPLT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):